SGMT (Sagimet Biosciences) Future Price to Earnings

Corporate emblem and logo of Sagimet (SGMT)

The primary threats to Sagimet Biosciences (SGMT) remain the uncertainty surrounding the results of clinical trials for liver pathology treatments and high development costs. Meanwhile, the company retains its staff of leading biochemists through stock options, selectively recruiting trial specialists. This price trend shown below with the 0.00 indicator complements the business profile, which relies on the creation of innovative medications to combat obesity and diabetes.

SGMT - Sagimet Biosciences, Inc. Projected Price to Earnings Ratio over the range 02/21/2024 - 11/18/2026

Analytical breakdowns for Sagimet Biosciences

- current price and projected stock value:
General company analysis:SGMT sagimet.com
Brand item of Sagimet Biosciences Inc

Investors use this tool to filter assets based on fundamental stability. The metric compares the current market value of the business with expected net profit, stripping market noise from the trend. For Sagimet Biosciences (SGMT), which is preparing a NASH drug for market launch, this calculation reflects the priced-in expectations for future commercialization. An analysis of the company's forward P/E NTM allows for an assessment of the asset's overbought status. The forward P/E NTM price action signals the balance between growth potential and correction risk.

Competitors of Sagimet Biosciences (SGMT)

Projected Price to Earnings ASND (Ascendis Pharma Inc.)|MDGL (Madrigal Corp) - Future Price to Earnings Multiple|Future Price to Earnings corcept.com CORT|RYTM - Projected Price to Earnings|Akero Corp - Forward P/E Multiple|Projected Price to Earnings Ratio Metsera Corp|MLTX (MoonLake) - Projected Price to Earnings|CRNX: Market Cap to Future Earnings Ratio|NAMS (NewAmsterdam Pharma Corp) - Forward P/E Multiple|Forward P/E Multiple Soleno Therapeutics|Forward P/E Multiple FOLD|Future Price to Earnings ETNB (89bio Inc)|Future Price to Earnings agios.com AGIO|Structure Corp (GPCR) - Projected Price to Earnings Ratio|MDXG - Future Price to Earnings|RZLT: Future Price to Earnings|LXRX: Forward P/E Multiple|MBX - Market Cap to Projected Earnings|Future Price to Earnings Altimmune Pharma|Aardvark Pharma (AARD) - Market Cap to Projected Earnings|Future Price to Earnings bioagelabs.com (BIOA)|Projected Price to Earnings Biomea Fusion, Inc. BMEA|Future Price to Earnings Quince QNCX|GUTS (Fractyl Health Inc.) - Price to Expected Earnings Ratio|VTVT: Projected Price to Earnings|Forward Price to Earnings Multiple agapeatpgroup.com (ATPC)|PLUR (Pluri) - Projected Price to Earnings|Price to Future Earnings Ratio SYBX|Future Price to Earnings Lipocine Corporation|matinasbiopharma.com (MTNB) - Market Cap to Projected Earnings|Forward P/E Multiple SPRB|Projected Price to Earnings Galecto, Inc. GLTO|Future Price to Earnings Carmell Corporation CTCX|Future Price to Earnings Multiple LUMO|ONVO: Projected Price to Earnings|Future Price to Earnings Multiple RDUS (Radius Recycling Inc.)